Summary: a-and γ-enolase isoenzyme substance concentrations were measured in serum and plasma from healthy subjects and from 174 patients with different solid tumours. While α-enolase was found to be increased in the plasma of patients with tumours of quite different origin, γ-enolase apparently reflected malignancies of the neuroendocrine System. Before the beginning of the cytotoxic therapy γ-enolase was increased above the upper limit of the reference r nge (10 μg/l) in 27/27 patients (100%) suffering from small cell lung cancer. Most patients with squamous cell carcinoma of the lung or with prostatic cancer exhibited normal γ-enolase, while both tumour types produced high plasma substance concentrations of the aisoenzymes of enolase. Wertigkeit der Enolase-Isoenzyme als TumormarkerZusammenfassung: Die Substanzkonzentrationen von a-und γ-Enolase-Isoenzym wurden im Serum und Plasma von Gesunden und 174 Patienten mit unterschiedlichen, soliden Tumoren bestimmt. W hrend sich die α-Enolase-Formen als relativ unspezifisch, d. h. bei unterschiedlichen Tumoren im Plasma erh ht fanden, zeigten die γ-Isoenzyme maligne Erkrankungen des neuroendokrinen Systems relativ spezifisch an. Bei einem Kollektiv von 27 Patienten mit kleinzelligem Lungen-Karzinom fand sich vor der Therapie in 100% der F lle ein Anstieg der γ-Enolase ber den oberen Referenzwert (10 Hg/l). Patienten mit Plattenepithel-Karzinom der Lunge und solche mit Prostata-Karzinomen hatten in der Regel normale γ-Enolase-, dagegen erh hte aEnolase-Substanzkonzentrationen im Plasma. Introdiictionstudied and characterized by Marangos* group (2). Cells related to the amine precursor uptake and de-Recently it was found that small cell lung carcinoma carboxylation (APUD) System (1) share several com-cells also express APUD ceU-specific markers such s mon properties, which include the ability to produce bombesin, L-dopa decarboxylase and γ-enolase (3). and secrete peptides, the presence of storage vesicles The first report by Carney et al. (4) that γ-enolase is and a similar enzyine and isoenzyme pattern. One of elevated to a high degree in the serum of most small the marker proteinsforthis System is the γ-isoenzyme cell lung cancer patients was confirmed by others of enolase (neuron-specific enolase, NSE) extensively (5 -14), but it became evident that patients suffering
This is a preliminary analysis of the AIO-Testicular Tumour Study Group trial in patients with disseminated bulky testicular cancer. Treatment plan: cisplatin 35 mg/m2 days 1-5, VP-16 120 mg/m2 days 1-5 (two daily divided doses), bleomycin 15 mg/m2 days 1, 8, 15. Of 98 patients at present evaluable 63% had complete remission or have no evidence of disease (CR/NED), 30% had partial remission (PR) and 7% had no change or progressive disease (NC/P). Relapse-free survival is 93% for the CR/NED group after a median follow up of 2.2 years: the overall survival for the entire patient population is 70%. Toxicity included predominantly granulocytopenic fever and infection with septicaemia, thrombocytopenia, nausea, vomiting, neurotoxicity and lung toxicity, with 7% fatal toxicity. A prospective randomized trial is warranted to evaluate the apparent superior activity of ultra high dose cisplatin in combination with VP-16 and bleomycin.
Background: Hematologic growth factors may allow dose intensification of chemotherapy, possibly leading to improved treatment results in high-grade malignant non-Hodgkin’s lymphomas. In the present study, the feasibility of reducing the time intervals between treatment cycles of chemotherapy was examined. Patients and Methods: In 43 patients with high-grade malignant lymphomas, intervals between chemotherapy cycles of the VIM/CHOP regimen were reduced from the original 21 to 17 and even 14 days. r-metHuG-CSF (Filgrastim) doses of 5 μg/kg were administered subcutaneously for 10 or 9 days after each treatment cycle. Results: Time interval reduction as scheduled was achieved in 76% of the cycles. Treatment delays of more than 2 days for medical reasons occurred in only 4% of cycles. Side effects of r-metHuG-CSF treatment were observed in only 11 patients who experienced bone pain, which was severe in 2 patients. Other toxicity was chemotherapy-related and seldom severe. Conclusions: With r-metHuG-CSF (Filgrastim) support, treatment intervals of VIM/CHOP chemotherapy can safely be reduced. Whether this will lead to better treatment results needs further examination.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.